Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Short-term Investments (2018 - 2022)

Historic Short-term Investments for Spero Therapeutics (SPRO) over the last 5 years, with Q1 2022 value amounting to $49.9 million.

  • Spero Therapeutics' Short-term Investments rose 2904.44% to $49.9 million in Q1 2022 from the same period last year, while for Mar 2022 it was $49.9 million, marking a year-over-year increase of 2904.44%. This contributed to the annual value of $33.8 million for FY2021, which is 1889.58% down from last year.
  • Latest data reveals that Spero Therapeutics reported Short-term Investments of $49.9 million as of Q1 2022, which was up 2904.44% from $33.8 million recorded in Q4 2021.
  • Spero Therapeutics' Short-term Investments' 5-year high stood at $90.7 million during Q3 2018, with a 5-year trough of $2.0 million in Q3 2020.
  • In the last 5 years, Spero Therapeutics' Short-term Investments had a median value of $33.8 million in 2021 and averaged $37.5 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first plummeted by 9585.16% in 2020, then skyrocketed by 42737.26% in 2021.
  • Spero Therapeutics' Short-term Investments (Quarter) stood at $81.4 million in 2018, then tumbled by 35.7% to $52.3 million in 2019, then dropped by 20.3% to $41.7 million in 2020, then decreased by 18.9% to $33.8 million in 2021, then surged by 47.42% to $49.9 million in 2022.
  • Its Short-term Investments stands at $49.9 million for Q1 2022, versus $33.8 million for Q4 2021 and $10.6 million for Q3 2021.